associated with the BIMO program review of the PMA and the performance 
of any clinical or nonclinical inspections. FDA will monitor its BIMO 
preapproval inspection program and include this information in its 
annual performance report to Congress.
    This draft guidance provides information about the administrative 
process and timeframes within which the BIMO review of the PMA clinical 
and nonclinical sections should be completed. Use of this draft 
guidance should facilitate FDA's timely review